HC Wainwright Weighs in on Minerva Neurosciences, Inc.’s Q2 2024 Earnings (NASDAQ:NERV)

Minerva Neurosciences, Inc. (NASDAQ:NERV) – Research analysts at HC Wainwright dropped their Q2 2024 earnings per share estimates for shares of Minerva Neurosciences in a research note issued to investors on Thursday, May 2nd. HC Wainwright analyst D. Tsao now forecasts that the biopharmaceutical company will post earnings of ($0.97) per share for the quarter, down from their prior estimate of ($0.77). HC Wainwright currently has a “Neutral” rating and a $7.00 target price on the stock. The consensus estimate for Minerva Neurosciences’ current full-year earnings is ($1.89) per share. HC Wainwright also issued estimates for Minerva Neurosciences’ Q3 2024 earnings at ($0.73) EPS, Q4 2024 earnings at $0.95 EPS, FY2024 earnings at ($1.89) EPS, FY2025 earnings at ($3.60) EPS, FY2026 earnings at ($4.36) EPS, FY2027 earnings at ($1.05) EPS and FY2028 earnings at $0.66 EPS.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.07.

Separately, StockNews.com raised Minerva Neurosciences from a “sell” rating to a “hold” rating in a research note on Thursday, May 2nd.

Minerva Neurosciences Stock Up 6.4 %

Shares of Minerva Neurosciences stock opened at $2.49 on Monday. The firm has a market cap of $17.41 million, a PE ratio of -0.56 and a beta of 0.27. The company’s fifty day simple moving average is $2.57 and its two-hundred day simple moving average is $5.26. Minerva Neurosciences has a 12-month low of $2.29 and a 12-month high of $13.49.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.